SPRO Stock Summary and Trading Ideas (Spero Therapeutics | NASDAQ:SPRO)

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.

As of January 31, 2025, SPRO stock price was flat at $0.87 with 13,456 million shares trading.

SPRO has a beta of 1.48, meaning it tends to be more sensitive to market movements. SPRO has a correlation of 0.14 to the broad based SPY ETF.

SPRO has a market cap of $47.43 million. This is considered a Sub-Micro Cap stock.

Last quarter Spero Therapeutics reported $13 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.04.

In the last 3 years, SPRO traded as high as $12.04 and as low as $.68.

The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC.

SPRO has underperformed the market in the last year with a return of -43.9%, while the SPY ETF gained +25.6%. In the last 3 month period, SPRO fell short of the market, returning -32.6%, while SPY returned +5.4%. However, in the most recent 2 weeks SPRO has outperformed the stock market by returning +4.2%, while SPY returned +3.0%.

SPRO support price is $.83 and resistance is $.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.